Conference Coverage
Latest News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
Conference Coverage
Breast cancer experts and other HCPs disagree on treatment strategies for early BC
It’s challenging for some oncologists to keep up with the nuances of a rapidly changing field, said the author of new research.
Conference Coverage
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
Conference Coverage
Vulvodynia: A little-known and treatable condition
A patient’s quality of life “can be significantly improved with a personalized therapeutic approach,” said Dr. Pina Belfiore.
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Prenatal sleep problems, depression linked to poorer outcomes
Screening pregnant patients for sleeping problems and for prenatal depression early in pregnancy may help identify and prevent later problems.
Conference Coverage
Up-front pembro plus chemo boost survival in cervical cancer
Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers...
Conference Coverage
‘Huge step forward’ in advanced ovarian cancer
A preplanned interim analysis revealed that the addition of durvalumab and olaparib was associated with a 37% improvement of PFS, compared with...
Conference Coverage
Phone support helps weight loss in patients with breast cancer
After 6 months, patients who received telephone coaching and health education lost 9.7 pounds.
Conference Coverage
Breast cancer: Meta-analysis supports ovarian suppression/ablation
Controlling estrogen seems to give premenopausal women a lifespan boost, but strategy remains uncommon.
Conference Coverage
Surgical de-escalation passes clinical test in low-risk cervical cancer
‘Practice-changing’ results could reduce long-term survivor effects among qualifying patients.